NCT02590809 (Light-CARMIDO) is a Phase 2 clinical trial of Treatment BX1514M in Hypertrophic Cardiomyopathy, sponsored by University Hospital, Bordeaux.

Who is sponsoring NCT02590809?

NCT02590809 is sponsored by University Hospital, Bordeaux.

What drugs are being tested in NCT02590809?

Interventions in NCT02590809: Treatment BX1514M, Placebo, Walk distance test, Exercise echocardiography.

What condition does NCT02590809 study?

NCT02590809 studies Hypertrophic Cardiomyopathy.

Is NCT02590809 still recruiting?

NCT02590809 is currently completed. Last updated 10 February 2022.

Last reviewed 2022-02-10 · How we verify

NCT02590809: Light-CARMIDO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hypertrophic Cardiomyopathy Symptom Release by BX1514M

Completed Phase 2 Last updated 10 February 2022

What this trial tests

Phase 2 trial testing Treatment BX1514M in Hypertrophic Cardiomyopathy in 38 participants. Completed in 6 July 2016.

Timeline

7 October 2015

Primary endpoint
6 July 2016

6 July 2016

Quick facts

Lead sponsor	University Hospital, Bordeaux
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	38
Start date	7 October 2015
Primary completion	6 July 2016
Estimated completion	6 July 2016
Sites	1 location across France

Drugs / interventions tested

Treatment BX1514M — full drug profile →
Placebo
Walk distance test
Exercise echocardiography

Conditions studied

Hypertrophic Cardiomyopathy — all drugs for Hypertrophic Cardiomyopathy →

Sponsor

University Hospital, Bordeaux

Who can join

Adults 18 to 80, any sex, with Hypertrophic Cardiomyopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Hypertrophic cardiomyopathy (HCM) is the most frequent genetic cardiac disease characterized by an asymmetric hypertrophic. In two third of patients, an obstruction to blood ejection is observed within the left ventricle which is named left ventricular outflow tract obstruction (LVOTO). This phenomenon can occur at rest or during exercise and is associated with symptoms such as dyspnea, dizziness or chest pain that can significantly limit day life adaptation. To now, medical or interventional treatments such as betablocacker, calcium blockers or septal alcoholisation or surgery present with a limited efficiency. Recent studies from investigators group revealed new concepts about the role of venous return to the LVOTO. Therefore the investigators hypothesis that BX1514M generating a venous vascular constriction, could improve symptoms of HCM patients by reducing LVOTO.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Hypertrophic Cardiomyopathy

Currently open trials in the same condition.

NCT07361289 — A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopa · recruiting
NCT06490250 — Comparison of the Effects of Inspiratory Muscle Training and Baduanjin Exercises in Hypertrophic Cardiomyopathy Patients · NA · recruiting
NCT06573723 — Institutional Registry of Rare Diseases · recruiting
NCT06549608 — A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada · active not recruiting
NCT05939700 — Mavacamten Pregnancy Surveillance Program · recruiting

Other University Hospital, Bordeaux trials

Trials by the same sponsor.

NCT07506928 — NEURO - Prognostication Using Late Somatosensory Evoked - Potentials · NA · not yet recruiting
NCT07524036 — Impact of a Nursing Educational Consultation on the Patient's Adherence to Their Post-stroke Care Plan. · NA · not yet recruiting
NCT07527494 — Digital MEDIcal TWIN for the Prediction of Arrhythmic Sudden Cardiac Death After a Myocardial Infarction · NA · not yet recruiting
NCT07527442 — Efficacy and Safety of Circumcision Alone on Risk of Febrile Urinary Tract Infections in Boys With Posterior Urethral Va · Phase 2 · not yet recruiting
NCT07478523 — FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02590809 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Bordeaux
Last refreshed: 10 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02590809.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing